Objective To investigate the safety and tolerability of eslicarbazepine acetate (ESL), a once-
daily oral anti-seizure drug (ASD), in older and younger adult patient populations. Methods …

Background: P-glycoprotein, encoded by ABCB1 (or MDR1), may contribute to drug
resistance in epilepsy by limiting gastrointestinal absorption and brain access to antiseizure …

OBJECTIVE: Investigate the efficacy of eslicarbazepine acetate (ESL) as adjunctive therapy
for partial-onset seizures (POS) with/without concomitant carbamazepine (CBZ) …

Objectives Carbamazepine (CBZ) is one of the oldest, yet first line drugs for treating
epilepsy. However, there is a large inter-individual difference in requirement of maintenance …

Background Epilepsy is a common neurological disease but around 30% of patients fail to
respond to antiepileptic drug (AED) treatment. Genetic variation of the ATP-binding cassette …

Background: Interindividual variations in the efficacy of antiseizure medications make
epilepsy treatment challenging. This is due to genetic factors such as gene polymorphisms …

Abstract Background Antiepileptic drugs (AEDs) are effective medications available for
epilepsy. However, many patients do not respond to this treatment and become resistant …

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Background Previous studies have shown that the rs717620 polymorphism in ABCC2, the
gene encoding multidrug resistance protein 2, influences the therapeutic response to anti …